UBS Group’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,198
| Closed | -$14K | – | 10416 |
|
|
2023
Q1 | $14K | Buy |
5,198
+3,223
| +163% | +$12.3K | ﹤0.01% | 7368 |
|
|
2022
Q4 | $7.88K | Buy |
1,975
+1,973
| +98,650% | +$12.1K | ﹤0.01% | 8848 |
|
|
2022
Q3 | $0 | Hold |
2
| – | – | ﹤0.01% | 11532 |
|
|
2022
Q2 | $0 | Sell |
2
-331
| -99% | -$3.1K | ﹤0.01% | 11498 |
|
|
2022
Q1 | $6K | Buy |
333
+146
| +78% | +$4.68K | ﹤0.01% | 9060 |
|
|
2021
Q4 | $12K | Sell |
187
-39
| -17% | -$2.27K | ﹤0.01% | 8622 |
|
|
2021
Q3 | $15K | Buy |
226
+221
| +4,420% | +$15.8K | ﹤0.01% | 7547 |
|
|
2021
Q2 | $0 | Buy |
5
+3
| +150% | +$162 | ﹤0.01% | 10104 |
|
|
2021
Q1 | $0 | Sell |
2
-380
| -99% | -$28.8K | ﹤0.01% | 9717 |
|
|
2020
Q4 | $22K | Buy |
+382
| New | +$22.2K | ﹤0.01% | 6891 |
|
|
2020
Q3 | – | Sell |
-213
| Closed | -$27K | – | 8607 |
|
|
2020
Q2 | $27K | Buy |
213
+135
| +173% | +$11.9K | ﹤0.01% | 6359 |
|
|
2020
Q1 | $4K | Buy |
78
+45
| +136% | +$4.41K | ﹤0.01% | 7435 |
|
|
2019
Q4 | $4K | Buy |
33
+30
| +1,000% | +$4.06K | ﹤0.01% | 7698 |
|
|
2019
Q3 | $0 | Sell |
3
-40
| -93% | -$8.05K | ﹤0.01% | 8386 |
|
|
2019
Q2 | $13K | Buy |
43
+19
| +79% | +$7.92K | ﹤0.01% | 6917 |
|
|
2019
Q1 | $10K | Sell |
24
-94
| -80% | -$41.1K | ﹤0.01% | 6838 |
|
|
2018
Q4 | $54K | Buy |
118
+115
| +3,833% | +$71.3K | ﹤0.01% | 6026 |
|
|
2018
Q3 | $3K | Sell |
3
-39
| -93% | -$25.7K | ﹤0.01% | 7685 |
|
|
2018
Q2 | $25K | Buy |
42
+39
| +1,300% | +$25.4K | ﹤0.01% | 6549 |
|
|
2018
Q1 | $2K | Hold |
3
| – | – | ﹤0.01% | 7578 |
|
|
2017
Q4 | $1K | Sell |
3
-17
| -85% | -$6.49K | ﹤0.01% | 7746 |
|
|
2017
Q3 | $6K | Buy |
20
+14
| +233% | +$5.32K | ﹤0.01% | 7171 |
|
|
2017
Q2 | $3K | Sell |
6
-104
| -95% | -$78.8K | ﹤0.01% | 7317 |
|
|
2017
Q1 | $137K | Buy |
+110
| New | +$52.9K | ﹤0.01% | 4894 |
|
|
2016
Q4 | – | Sell |
-35
| Closed | -$14K | – | 8141 |
|
|
2016
Q3 | $14K | Sell |
35
-114
| -77% | -$51K | ﹤0.01% | 6571 |
|
|
2016
Q2 | $73K | Buy |
+149
| New | +$75.6K | ﹤0.01% | 5248 |
|
|
2016
Q1 | – | Sell |
-33
| Closed | -$26K | – | 8360 |
|
|
2015
Q4 | $26K | Buy |
+33
| New | +$32.4K | ﹤0.01% | 6480 |
|
|
2015
Q3 | – | Sell |
-2
| Closed | -$5K | – | 8731 |
|
|
2015
Q2 | $5K | Buy |
+2
| New | +$5.11K | ﹤0.01% | 7897 |
|
UBS Group's HTGM Position: Q2 2023 in Review
UBS Group sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2023, closing a stake of 5,198 shares — an estimated $14K sold.
UBS Group first reported a position in HTGM in Q2 2015 and held it in 28 quarters. The position peaked at $137K in Q1 2017. 0 funds tracked by Wall St. Rank hold HTGM as of Q2 2023.
- UBS Group reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 5,198 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2023, an estimated $14K.
- UBS Group first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 28 quarters.
- UBS Group's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $137K in Q1 2017.
- 0 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.